Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | M77CC | — |
adult patient was administered by mistake another BOOSTRIX dose "...too early; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 60-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number M77CC, expiry date 19-MAR-2027) for prophylaxis. Previously administered products included BOOSTRIX (13-JAN-2020 the patient received a booster dose). On 30-JAN-2025, the patient received Boostrix. On 30-JAN-2025, an unknown time after receiving Boostrix, the patient experienced drug dose administration interval too short (Verbatim: adult patient was administered by mistake another BOOSTRIX dose "...too early). The outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-FEB-2025 Medical Assistant reported the patient was administered by mistake another Boostrix dose too early, which led to shortening of vaccination schedule. The reporter consented to follow up.